Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Pharma-Bio Serv (PBSV) Divestments (2018)

Pharma-Bio Serv filings provide 1 years of Divestments readings, the most recent being $2.0 million for Q4 2018.

On a quarterly basis, Divestments changed N/A to $2.0 million in Q4 2018 year-over-year; TTM through Jul 2019 was $2.0 million, a N/A change, with the full-year FY2018 number at $2.0 million, up 606.67% from a year prior.
Divestments hit $2.0 million in Q4 2018 for Pharma-Bio Serv.
In the past five years, Divestments ranged from a high of $2.0 million in Q4 2018 to a low of $2.0 million in Q4 2018.